tivdak
Generic: tisotumab·Brand: Tivdak
tivdak: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
tivdak evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
Source-backed records connect tivdak to SGEN; that link alone does not prove the drug works.
What to watch
Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected
Prepared research question
How could tivdak → SGEN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| Seagen Inc. (SGEN) | Approved |
| Seagen Inc. (SGEN) | Approved |
Clinical Trials (1)
A PROSPECTIVE LOW-INTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK® IN RECURRENT OR METASTATIC CERVICAL CANCER
Primary endpoint: Type, incidence and severity of ocular adverse events (AEs)
Interventionalopen100 targetStarted 2025-05Completion 2028-1250 sites · United StatesPfizer
FDA Decisions1 records
Frequently asked questions
Who is developing tivdak?
tivdak is being developed by Seagen Inc..
How many clinical trials involve tivdak?
BioSniper tracks 1 clinical trial involving tivdak.
What is tivdak's latest FDA decision?
The most recent tracked FDA decision for tivdak is Approval, dated September 20, 2021.